A Study to Evaluate AXR-159 Ophthalmic Solution in Patients With Dry Eye Disease

Summary

Protocol AXR201701 is a multicenter, double-masked, vehicle-controlled, randomized, parallel group study carried out in 2 stages (Stage 1: AXR-159 Ophthalmic Solution (30 mg/mL or 50 mg/mL); Stage 2: AXR-159 Ophthalmic Solution (3 mg/mL, 30 mg/mL or 50 mg/mL) in approximately 430 patients diagnosed with dry eye disease (DED).

Timeline

Start

2018-06-26

Primary completion

2018-12-28

Completion

2019-01-09

Drugs

Indications